Podcasts about tumors

BUFFALO, NY - May 9, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on May 8, 2025, titled “METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis." In this study, researchers Jayasree Peroth Jayaprakash, Pragati Karemore, and Piyush Khandelia from the Birla Institute of Technology and Science, India, discovered that a molecule called METTL3 contributes to the development and spread of oral squamous cell carcinoma (OSCC). The study shows that METTL3 increases the levels of a small RNA molecule called miR-146a-5p, which blocks SMAD4, a key tumor-suppressing gene. These findings help explain why oral cancers are difficult to treat and may offer a new target for more effective therapies. Oral squamous cell carcinoma is a common and aggressive cancer affecting the mouth and throat. It has a high death rate, mainly due to late detection, treatment resistance, and the cancer's ability to invade nearby tissues. In this study, the researchers focused on METTL3, an enzyme that adds chemical tags known as m6A marks to RNA, which change how genetic information is used by cells. They found that METTL3 is unusually active in OSCC cells, causing an increase in miR-146a-5p. This molecule, in turn, blocks the function of SMAD4, which helps control how cells grow and die in our bodies. “METTL3, the primary m6A RNA methyltransferase, is significantly upregulated in OSCC cells leading to increased global m6A levels.” When METTL3 was reduced or chemically blocked, miR-146a-5p levels dropped and SMAD4 levels increased. This shift slowed the growth of cancer cells, increased their death, and made them less likely to spread. When researchers reintroduced miR-146a-5p or lowered SMAD4 levels again, the cancer-promoting behavior returned. These results show that the METTL3–miR-146a-5p–SMAD4 pathway plays a key role in OSCC. The findings open up new possibilities for treatment. Drugs that block METTL3 or miR-146a-5p or that restore SMAD4 could slow or stop tumor growth. One such drug, STM2457, which targets METTL3, has already shown promise in lab studies. As research progresses, targeting this molecular pathway may offer a new strategy in treating OSCC. This discovery improves our understanding of how OSCC develops and avoids the body's defenses. By interfering with this newly discovered pathway, future treatments may become more successful, improving survival rates and quality of life for people with this disease. DOI - https://doi.org/10.18632/oncotarget.28717 Correspondence to - Piyush Khandelia - piyush.khandelia@hyderabad.bits-pilani.ac.in Video short - https://www.youtube.com/watch?v=o5XuDlcIma8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28717 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this radiology lecture, we review the ultrasound appearance of giant cell tumor of the tendon sheath! Key teaching points The post Ultrasound of Giant Cell Tumor of the Tendon Sheath appeared first on Radquarters.

Show #2405 Show Notes: Luke 8: https://www.biblegateway.com/passage/?search=Luke%208&version=KJV ‘Manifest’: https://webstersdictionary1828.com/Dictionary/manifest LAN Events: https://thelibertyactionnetwork.com/calendar/ Mathematics of the Mound Builders: https://www.youtube.com/watch?v=NZDYuo2bGrM Parasites in Tumor: https://www.facebook.com/reel/919497673449737 Cancer-Fighting benefits of Ivermectin: https://choiceclips.whatfinger.com/2025/05/07/the-remarkable-cancer-fighting-benefits-of-ivermectin-ivermectin-can-actually-kill-cancer-stem-cells-which-are-often-resistant-to-chemotherapy/ New Cancer Treatment Protocol: https://www.thegatewaypundit.com/2024/10/new-cancer-treatment-protocol-featuring-horse-dewormer-ivermectin/ Government Admits it knew covid […]

[include file=get-in-itunes.html] It was nice to have my partner in crime back! Today we had another Free For All Friday show which was a lot of fun. We had our first caller call in and that was a lot of fun also. Stella from New York shared some of her experiences with different things she’s […] The post Updates On Kate’s Silent Retreat, Tumors Coming Out During Coffee Enemas, Inspirational Information, Listeners Call In & More! appeared first on Extreme Health Radio.

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Bold and the Beautiful 2-week spoilers for May 5-16, 2025 see Liam Spencer's (Scott Clifton) fatal tumor diagnosis is set to ripple across the Forrester and Logan families. Steffy Forrester (Jacqueline MacInnes Wood) becomes the main advocate for transparency, pushing Liam to tell Hope Logan (Annika Noelle) about his health situation on the CBS soap opera.  Bold spoilers see Carter Walton (Lawrence Saint-Victor) continues to express his feelings for Hope, creating a tense love triangle. The Logan sisters, Brooke (Katherine Kelly Lang) and Donna Logan (Jennifer Gareis), also grapple with their romantic entanglements, with Ridge Forrester (Thorsten Kaye) and Deacon Sharpe (Sean Kanan) respectively.  Spoilers for Bold and Beautiful see this two-week saga also introduces a potential bonding moment between long-time rivals, Hope and Steffy. Finally, Bill Spencer (Don Diamont), Liam's father, is set to discover his son's prognosis, leading to a tense and emotional confrontation the weeks of 5/5-5/16, 2025. Visit our Bold and the Beautiful section of Soap Dirt: https://soapdirt.com/category/bold-and-the-beautiful/ Listen to our Podcasts: https://soapdirt.podbean.com/ Check out our always up-to-date Bold and the Beautiful Spoilers page at: https://soapdirt.com/bold-and-the-beautiful-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

In dieser Episode des Podcasts "Krebs als zweite Chance" spricht Kendra Zwiefka mit Nadine, die dreimal an Brustkrebs erkrankt ist. Nadine teilt ihre persönliche Geschichte, die Herausforderungen, die sie während ihrer Diagnosen und Behandlungen erlebt hat, und betont die Bedeutung von Selbstbestimmung und alternativen Heilmethoden. Sie spricht auch über ihre Schwangerschaft während der Krebserkrankung und die damit verbundenen Schwierigkeiten. Nadines inspirierende Geschichte ermutigt andere, ihren eigenen Weg in der Krebsbehandlung zu finden und auf ihre Intuition zu hören. In diesem Gespräch reflektiert Nadine über ihre Erfahrungen mit Brustkrebs, die Herausforderungen der Mutterschaft nach der Diagnose und ihre Reise zur persönlichen Entwicklung durch Aromatherapie und Coaching. Sie spricht über die Rückkehr zur Normalität nach der Operation, die Dringlichkeit ihrer erneuten Untersuchung und die schockierende Entdeckung eines neuen Tumors. Nadine teilt ihre Gedanken über Verantwortung und die Entscheidungen, die sie in Bezug auf ihre Behandlung getroffen hat. In diesem inspirierenden Gespräch teilen Kendra und Nadine ihre Erfahrungen mit Krebsdiagnosen, Medikamenten und den Herausforderungen, die damit verbunden sind. Nadine spricht über ihre drei Krebsdiagnosen und wie sie gelernt hat, mit den Nebenwirkungen der Medikamente umzugehen. Sie betont die Bedeutung der psychonkologischen Beratung und wie sie anderen Menschen helfen möchte, die ähnliche Erfahrungen machen. Das Gespräch endet mit ermutigenden Botschaften über das Leben mit Krebs und die Wichtigkeit, sich selbst an erste Stelle zu setzen. Ich hoffe sehr, dass dir die Folge gefallen hat und du etwas mitnehmen konntest. https://www.nadinekalkstein.de/ https://www.instagram.com/psychoonkologischeberatung/ Schreib mir von Herzen gern, eine positive Bewertung oder wenn du magst, abonniere meinen Podcast, um keine Folge zu verpassen. Ich würde mich riesig über deine Gedanken zu dieser Folge freuen, schau gern bei Instagram vorbei unter der aktuellen Podcast Folge und kommentiere dort deine Gefühle und Gedanken. Was konntest du für dich mitnehmen? Denk immer daran, DU bist nicht allein. Ich freue mich schon auf die nächste Folge mit dir. Bleib gesund! Danke, dass es dich gibt. Teile den Podcast mit den Menschen, die genau jetzt Mut, Kraft und Hoffnung brauchen. Heute möchte ich dir noch einen ganz wundervollen Podcast vorstellen, von der lieben Franziska mit dem Podcast Lebe Selbstvoll, Franziska interviewt Frauen zum Thema Krebs, schau gerne bei ihr vorbei, sie macht das ganz wundervoll. https://open.spotify.com/show/4rPwPlb8XFc9O07FoYQcGx Heute möchte ich von Herzen gerne Werbung machen für die wundervolle Cornelia, sie war auch schon öfters in meinem Podcast zu Gast, falls du es noch nicht getan hast, hör dir unbedingt dazu die 200. Folge an da teilt Cornelia eine wundervolle Meditation mit dir. Hier findest du mehr zu Conny. https://myablefy.com/s/cornelia-moennig/healing-session-dein-goldenes-licht-und-seine-heilkraft-aa4ee71d Hast du deine eigene Krebs Erfahrung, die du mit der Welt teilen möchtest? Oder hast du jemanden aus deiner Familie an Krebs verloren? Ich möchte jedem eine Chance geben, über das Thema Krebs zu sprechen. Fühl dich von Herzen umarmt. Deine Kendra ❤

This episode summarizes recent updates on: Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)

Today on Beating Cancer Daily, Saranne discusses her journey of finding humor amidst the challenges of her Stage IV cancer diagnosis. Through her Tumor Humor Challenge, she seeks to inspire listeners by demonstrating how to uncover humor in their own cancer experiences. Saranne shares specific stories from her journey as a patient, survivor, and caretaker, emphasizing the vital role that laughter has played in her healing process. Her unique approach combines traditional medical treatments with complementary practices, offering a multidimensional perspective on cancer care.Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, Beating Cancer Daily and rated #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 is listened to in more than 100+ countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne 

Dr. Nimish Mohile and Dr. Jaishri Blakeley share the new rapid recommendation update to the therapy for diffuse astrocytic and oligodendroglial tumors in adults guideline. They review the evidence from the INDIGO trial that prompted this update, and how to incorporate the use of vorasidenib into clinical practice. They discuss the importance of molecular testing, particularly for IDH1 or IDH2 mutations and outstanding questions for treatment of patients with oligodendrogliomas and astrocytomas. Read the latest update, “Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update.” Transcript This guideline, clinical tools, and resources are available at http://www.asco.org/neurooncology-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in Journal of Clinical Oncology.   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Jaishri Blakeley from Johns Hopkins University School of Medicine and Dr. Nimish Mohile from the Department of Neurology and Wilmot Cancer Institute at the University of Rochester Medical Center, co-chairs on “Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: American Society of Clinical Oncology-Society for Neuro-Oncology Guideline Rapid Recommendation Update.”  Thank you for being here today, Dr. Blakeley and Dr. Mohile.  Dr. Jaishri Blakeley: Thank you.  Dr. Nimish Mohile: Thank you for having us.  Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Blakeley and Dr. Mohile who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.   So then, to jump into the content here, Dr. Mohile, could you start us off by describing what prompted this rapid update to the ASCO-SNO therapy for diffuse astrocytic and oligodendroglial tumors in adults guideline, which was previously published in 2021?  Dr. Nimish Mohile: Yeah. So the key reason for this update is the publication of a study in 2023. And this was a study called the INDIGO study that looked at a new class of therapies, something called IDH inhibitors. And in this study with a drug called vorasidenib, changed how we think about the treatment of oligodendrogliomas and astrocytomas, so particularly the grade 2 oligodendrogliomas and grade 2 astrocytomas. Because of the results of that study, we decided that we needed to do an update to inform clinicians about some of these changes and how we might approach these tumors differently today.  Brittany Harvey: Great. I appreciate that background. So then, based off the new data from the INDIGO study, what are the updated and new recommendations from the expert panel?  Dr. Nimish Mohile: So the key findings from the INDIGO study involved people who had grade 2 astrocytomas and grade 2 oligodendrogliomas. And in the setting after surgery, they were treated with vorasidenib, and what they found is that this delayed the time to next intervention. And the key aspect of that is that it delayed when we could start radiation and chemotherapy in these patients.   So what we did in the guidelines is that for both low grade oligodendrogliomas and low grade astrocytomas, we added one additional guideline statement. Our previous guideline in 2021 offered the options for observation or treatment with radiation and chemotherapy. And now in this guideline, we have options for observation, treatment with vorasidenib in those in whom we feel it is safe to defer radiation and chemotherapy, and then treatment with radiation and chemotherapy. So we've added in an additional option here. And the key message of the guideline is really on how, as clinicians, we think about using the vorasidenib and what the ideal setting for using the vorasidenib is.  Brittany Harvey: Excellent. It's great to hear about this new option for patients. So then you were just talking about how we think about who to offer this IDH inhibitor to. So, Dr. Blakeley, what should clinicians know as they implement these new recommendations into practice?  Dr. Jaishri Blakeley: Yes. So, first and foremost, let's go back to 2021, and a key note from those guidelines was the importance of molecular testing. And at that point, the importance of molecular testing, which in large part was focused on IDH1 or IDH2 mutations, was prognostic. We could say there's a difference in an IDH1 mutant astrocytoma and an IDH1 wild type astrocytoma, but we didn't have a specific therapeutic recommendation attached to that, like Dr. Mohile just said. And the big shift here is now we have a specific therapeutic for that population with IDH1 or IDH2 mutant glioma.   So for clinicians, we hope that they've been getting molecular testing on newly diagnosed glioma already, but now there's an additional motivation to do so because it may change your treatment plan in the right circumstance. So since the publication of the phase III INDIGO study that Dr. Mohile mentioned, and the FDA approval of vorasidenib, if you meet the specified criteria in the clinical trial - which the guidelines point out is a little different than what's on the FDA label, so clinicians might want to dig into that a little bit - then there is a treatment option that is new and different than combined chemoradiation or radiation alone or observation.  Brittany Harvey: I appreciate those clarifications there.   So then also, Dr. Blakeley, how does this update impact patients with astrocytic or oligodendroglial tumors?  Dr. Jaishri Blakeley: So first, patients also should know if they have IDH mutant gliomas. And this update only applies to people with IDH1/2 mutant glioma. Perhaps, we're not sure, it might only apply to people who are in the newly or newly-ish diagnosed category because the INDIGO study required that people were within the first five years of their surgical diagnosis and had not had other treatment. So there are a lot of people who have astrocytoma or oligodendroglioma who may or may not know their IDH1/2 status and may have already had another therapy - this update doesn't apply to them. We hope that future research will teach us about that. This update is for people who are newly diagnosed and just starting the journey to figure out the best therapy. It does say that if you do have that IDH1/2 alteration in your tumor, there is a drug therapy that is different from the drug therapies we would offer gliomas that do not have the IDH1/2 mutation.  Brittany Harvey: Absolutely. I think both that emphasis on molecular testing is very important and also thinking about that study inclusion criteria and how it impacts who's eligible for this treatment.   So then finally, Dr. Mohile, what are the outstanding questions about vorasidenib or other interventions for gliomas in adults?  Dr. Nimish Mohile: I think the key question for clinicians is exactly who we're going to use this in. The challenges with inclusion criteria in clinical trials is they don't actually always match what we're seeing in the clinic. And I think it brings up the question of, in low grade oligodendrogliomas which we think of as very slow growing tumors, do we have the option outside of the strict inclusion criteria to use that drug in other settings? I think it brings up the question for some clinicians in some of the higher grade tumors, in the grade 3 tumors, we don't yet have data in that area and our guideline doesn't address that. But I think some will be asking what the clinical activity of vorasidenib is in that setting. There are some suggestions that the IDH inhibitors may impact seizure control, and I think that that's data that we're continuing to wait on.   So I think that there's several outstanding questions there that we will have answers for hopefully in the next several years. I think the big question that we don't have an answer for and that will take a long time to know is whether the addition of vorasidenib in this setting actually improves how long people live. And given how long people with low grade oligodendrogliomas and low grade astrocytomas live today, we probably won't have an answer to that question for more than a decade.  Brittany Harvey: Definitely. We'll look forward to these ongoing developments and eventually longer term data on overall survival on these agents.   So, I want to thank you both so much for your work to rapidly include this information from this new trial. And thank you for your time today, Dr. Blakeley and Dr. Mohile.  Dr. Jaishri Blakeley: Thank you so much.  Dr. Nimish Mohile: Thank you Brittany.  Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/neurooncology-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. 

Neurosurgeon Stephen T. Magill, MD, PhD, leads a panel discussion on the management of tumors that compress the optic nerve. He is joined by Preeti J. Thyparampil, MD, a plastic and reconstructive surgeon, and Adam D. Baim, MD, a neuro-ophthalmologist.     The panel discusses tumors commonly associated with optic nerve compression, their impact on eye function, and the signs and symptoms that suggest a tumor is pressing on the optic nerve. They also delve into diagnostic strategies and treatment options, emphasizing key factors that determine the appropriate surgical approach.

In an interview with CancerNetwork®, William Kennedy, MD, a neuro-radiation oncologist at the Ivy Brain Tumor Center, provided expert insights into the current state of radiosurgery for central nervous system (CNS) tumors. Highlighting a diverse array of available radiosurgery platforms, he explained that institutions like the Ivy Brain Tumor Center frequently use noninvasive surgical techniques with complex monitoring systems. Kennedy further underscored the critical importance of having a nuanced understanding of each technology's capabilities and limitations, as well as those of the practicing oncologist. Emphasizing a high patient volume and a wide variety of cases at his own practice, he suggested that the expertise of the staff at the Ivy Brain Tumor Center positions them at the forefront of radiosurgery development. According to Kennedy, novel therapeutic strategies under development at Ivy Brain Tumor Center include the investigational agent AZD1390, which is being assessed in combination with radiotherapy after surgery for patients with newly diagnosed or recurrent glioblastoma. Despite the benefits that technology provide for research advancement and treatment, Kennedy posited that the multidisciplinary team is essential in ensuring the successful delivery of novel radiosurgery techniques. This integrated approach ensures that each patient benefits from an individualized plan that leverages the full potential of modern radiosurgery. “[D]espite all the great technologies that we have here at Ivy, what I think makes this place great, what makes me proud to work here, and what means the most for our patients is how closely we providers communicate with each other and how closely knit of a team we are,” Kennedy stated. “Being available, showing up to the tumor board, always picking up the phone when your colleague calls to discuss a tough case, and never being afraid to ask for help—all those things I have learned since I have been in practice here. Those are what make the difference, more than anything.”

Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient's perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx. “[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I'm not just a number, I'm a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett   Nancy Mallett Patient Advocate   Resources:  FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD  Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP  ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8  Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962  Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ    Funder Statement  This program is supported by AbbVie.   

Seminare: https://henningwilts.de/seminare   Kontaktdaten: Henning Wilts: https://henningwilts.de info@henningwilts.de https://www.instagram.com/henningwilts/ https://www.facebook.com/henning.wilts/ www.youtube.com/@HenningWiltsTierarzt https://www.linkedin.com/in/henning-wilts-376a8722b/ https://www.tiktok.com/@henningwilts    

You'll have no Kimchi, no horseradish and no Lt. Yar! Copycat Dipshitter. Tumor fruit. Port a Potty Perks. Shriracha Schmear. Gotta Go At Costco. Ass Cheek to Ass Cheek. I Dream Of GKneeeeeeeeeeeeeeeeeeeeeeeeeeeee! Neither a Miracle, Nor a Whip. Runner butt poo. Friendly Wackadoo. Non-Organic Dipshits. The darker the berry the hotter it is. John Wayne's Sperm. Tech Time with Mr. Las Vegas Tom Merritt. Alicia Stockholm Recommentals with Randy and Nicole and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

You'll have no Kimchi, no horseradish and no Lt. Yar! Copycat Dipshitter. Tumor fruit. Port a Potty Perks. Shriracha Schmear. Gotta Go At Costco. Ass Cheek to Ass Cheek. I Dream Of GKneeeeeeeeeeeeeeeeeeeeeeeeeeeee! Neither a Miracle, Nor a Whip. Runner butt poo. Friendly Wackadoo. Non-Organic Dipshits. The darker the berry the hotter it is. John Wayne's Sperm. Tech Time with Mr. Las Vegas Tom Merritt. Alicia Stockholm Recommentals with Randy and Nicole and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.

What does it take to deliver truly personalized, multidisciplinary care in testicular cancer? Get an inside look in this episode of BackTable Urology, where renowned testicular cancer experts Dr. Nabil Adra and Dr. Richard Matulewicz join host Dr. Aditya Bagrodia for a virtual tumor board session on the nuanced management of germ cell tumors. This episode was produced in collaboration with the Society of Urologic Oncology. --- SYNPOSIS The expert panel uses specific patient cases to review their decision-making processes on the use of surgery, chemotherapy, and radiation. They highlight the importance of a multidisciplinary approach, particularly for advanced disease and challenging surgical scenarios. The episode reviews patient-specific factors, standard treatment protocols, post-treatment surveillance, and the latest research. This episode also highlights the benefits of personalized cancer care. --- TIMESTAMPS 00:00 - Introduction 01:45 - Case Presentation: 23-Year-Old Male with Testicular Mass 02:14 - Initial Counseling and Management 04:03 - Orchiectomy and Post-Surgery 06:27 - Stage I Management 10:00 - Surveillance and Adjuvant Therapy 13:56 - Recurrence 23:13 - Case Study: 44-Year-Old with Non-Seminoma 28:14 - Case Study: 17-Year-Old with Developmental Delay and Cancer 29:42 - Chemotherapy Decisions 30:31 - Brain Imaging and Metastasis Predictions 33:54 - Chemotherapy Regimens 35:53 - Monitoring and Salvage Therapy 45:01 - Case Study: 21-Year-Old with Teratoma 55:21 - Concluding Thoughts --- RESOURCES Society of Urologic Oncology: https://suonet.org/home.aspx

Today on Beating Cancer Daily, Saranne shares her remarkable journey of using humor as a powerful coping tool during her battle with Stage IV cancer. Saranne recalls her early experiences with comedy, from watching Jackie Mason as a child to producing comedy shows for the Comedy Cures Foundation. She introduces the concept of "tumor humor," encouraging listeners to find laughter amidst their cancer treatment and challenges.Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, Beating Cancer Daily and rated #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 is listened to in more than 100+ countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne 

Dr. Joshua Kays, is a board-certified surgeon with additional training in Complex General Surgical Oncology. He specializes in the surgical treatment of liver, pancreas and bile duct disease.

Send us a textIn this episode of the Digital Pathology Podcast, I sit down with Dr. Yuri Nikiforov, founder of the World Tumor Registry, to explore how this global, open-access whole slide image platform contributes to cancer diagnostics, education, and research.We talk about how the registry allows pathologists, researchers, and patients to view curated whole-slide images from around the world, starting with thyroid tumors and expanding into other cancers like breast and lung. Learn how AI, molecular diagnostics, and editorial curation come together to build a truly global pathology tool that's free for everyone, forever.

I'm a 70-year-old woman with hip arthritis. Any recommendations?A treatment on the horizon for high Lipoprotein (a)?After chemotherapy to help shrink a tumor near my husband's spine, he now has numbness and neuropathy in his legsAnother study implicates meat, and now poultry and fish, in causing cardiovascular diseaseWhat do you think of Consumer Lab's recommendations on supplements?I take CoQ10, but I just heard about PQQ. What are your thoughts?

While rubbing her 3 year old daughter Chelsea's belly, Alison Hicks felt a lump which was shortly diagnosed as a Stage 4 Wilms Tumor. Chelsea fought this Pediatric  Kidney Cancer for nearly 2 years before passing away after a treatment protocol which was very difficult from the beginning to its end. As a result of Chelsea's battle and passing, Alison started the Chelsea Hicks Foundation which focuses on keeping a smile on Pediatric Cancer patients as they go through their impatient hospital treatments. 

In this solo episode of Light Warrior Radio, Dr. Karen Kan tackles a challenging spiritual paradox: can the elimination of “evil” truly uplift humanity—or does it reinforce the very darkness we claim to oppose?Drawing from both medical and metaphysical frameworks, Dr. Karen dives deep into:Tumor removal and its spiritual implicationsWhy "returning to Source" is just a euphemism for murderHow real change comes from healing, not annihilationThe Light Warrior path of self-mastery and shadow work

Het is de vijfde sterfdag van Louis van Dijk en zijn dochter Selma ontmoet de muzikanten waar hij mee heeft gespeeld. Matthijs Schraver onderzoekt in hoeverre de wietproef, die deze week een nieuwe fase in is gegaan, haalbaar is.

Lona Twins Talk All: Twin Sisters, Learning Disability, Mental Health, Tumor, CHISME & MORE!! Thanks to my sponsors: Find exactly what you're booking for on https://Booking.com, Booking.YEAH! • Don't forget to subscribe to the podcast for free wherever you're listening or by using this link: https://bit.ly/NochedePendejadasPodcast • If you like the show, telling a friend about it would be helpful! You can text, email, Tweet, or send this link to a friend: https://bit.ly/NochedePendejadasPodcast Follow Alannized on IG Follow Alannized on TikTok Follow Alannized on Twitter  Learn more about your ad choices. Visit podcastchoices.com/adchoices

041025 2nd HR Dr Bryan Ardis Nicotine and TUMORS Dosages and Ozempic Truth MUST LISTEN by Kate Dalley

Get More LVWITHLOVE Content Guests: Ian Mondrick – Comic Book Author, Co-Creator of STASH BOX www.stashboxcomic.com In this episode of the Lehigh Valley with Love Podcast, host George Wacker sits down with comedian, writer, and performer Kathleen Aldrich, whose brand-new one-woman show Tumor Baby premieres April 12 at SteelStacks in Bethlehem. We talk about how Kathleen got her start in the Lehigh Valley comedy scene over a decade ago, what it was like turning a real-life medical emergency into a heartfelt (and hilarious) show, and how Tumor Baby blends storytelling, vulnerability, and humor into something totally unique. From sketch comedy with Pigeon City to personal pieces in Dear Diary, Kathleen's journey is as inspiring as it is funny. You'll also get a behind-the-scenes look at how the show came together—from handwritten journal entries to Google Docs and years of performance experience—and why this isn't stand-up, but something more intimate and impactful. Catch Tumor Baby on Saturday, April 12 at 7:30 PM at SteelStacks Tickets & info: www.steelstacks.org/event/16872/tumor-baby Watch Episode https://youtube.com/live/fX8dV3Tt3DI www.lvwithlove.com Thank you to our Partners! WDIY Lehigh Valley Health Network Wind Creek Event Center Michael Bernadyn of RE/MAX Real Estate Molly’s Irish Grille & Sports Pub Banko Beverage Company Episode Recap Kathleen Aldrich and the Comedy of Crisis in TUMOR BABY “I've been talking about doing a one-woman show since 2014.” For comedian and writer Kathleen Aldrich, Tumor Baby isn't just a show—it's a culmination of more than a decade of finding her voice in the Lehigh Valley comedy scene. What started as strange abdominal pressure and a reluctant trip to the ER turned into a 10-pound tumor and, eventually, the foundation for a deeply personal, unexpectedly hilarious one-woman show. From Improvised Bits to Intimate Storytelling Kathleen's journey began in 2012 with improv classes at ArtsQuest, where she found her creative tribe and a passion for performance. Over the years, she honed her craft with local favorites like Dear Diary, Pigeon City Sketch, and Improvised Stand Up. Her work is rooted in real life—often uncomfortable, always honest—and Tumor Baby is no exception. “It's not stand-up,” she explains. “I'm a storyteller.” Kathleen weaves her cancer diagnosis into a broader narrative—childhood memories, messy relationships, weird blog awards, and moments that are just too good not to share. It's comedy that doesn't flinch. And it's all been years in the making. The Writing Process (and a Lot of Google Docs) So how do you write something like Tumor Baby? According to Kathleen, it all starts with pen and paper. She breaks down memories into moments, finds the funny in the pain, and then builds the show line by line. “I write down the significant moment first,” she says. “Then I ask—how do I make this funny?” With guidance and mentorship from fellow comic Alia Brown, Kathleen transformed those raw stories into a full-length show. It's not just about a tumor—it's about life, survival, and making people laugh in the face of the absurd. A Decade of Comedy and One Big Stage One of Kathleen's proudest moments? A sketch she wrote for Pigeon City called Sex in Senior Living—a drag parody imagining the Sex and the City crew as Golden Girls. “The crowd just loved it,” she says. “That moment… it was electric.” Now, with Tumor Baby, Kathleen steps into the spotlight solo. It's vulnerable, funny, and full of heart—and it all happens live this weekend. Don't Miss ItCatch Tumor Baby on Saturday, April 12 at 7:30 PM Bethlehem Visitor Center at SteelStacks Tickets & info: steelstacks.org

This week on the podcast I continue the conversation about humor and comedy with writer Kat Aldrich who is about to premiere her one-woman show Tumor Baby at Steelstacks in Bethlehem PA.Get your tickets at:https://www.steelstacks.org/event/168...Kat shares how therapeutic writing comedy has been for her in some serious times of her life and how excited she is to share this with the audience. Thank you to my sponsors Budget Through Life and Reinvented Threads for helping to make this content possible. Emily Hickox and Gabby Lynn are amazing women who are putting their incredible talents out into the universe and supporting me, which is incredible! Be sure to click on the links above to learn about both of their businesses. Follow Funny Wine Girl Jeannine on Facebook and Instagram for insight and funny moments. Please remember to subscribe and share. Reach out if you would like to be a sponsor this podcast or if you would like to suggest a guest.I appreciate you from the bottom of my heart and the bottom of my wine glass.

Bill Horan and Stacy Raine meet Seaford native Jesse Kinch - who is not only a successful rock musician, but he beat the odds stacked against him by overcoming a brain tumor.  We listen to his music and find out all about his career.

Could your body shrink a brain tumor by half before surgery? Taylor Dukes is proof that it is possible. In this episode, Taylor shares her journey from medical mission trips in Africa to discovering a plum-sized brain tumor in her frontal lobe with no symptoms, which offers invaluable wisdom for anyone navigating their own health challenges. Rather than immediately rushing to surgery, she practiced an integrative approach — metabolic ketosis, methylene blue, red light therapy, and molecular hydrogen oxygen, and with the results being nothing short of remarkable, her tumor shrinking by half before surgery. Your body's healing capacity is extraordinary when given the right tools. The question is: are you ready to discover what's possible for your own health? Join the Ultimate Human VIP community and gain exclusive access to Gary Brecka's proven wellness protocols today!: https://bit.ly/4ai0Xwg Connect with Taylor Dukes: Website: https://bit.ly/4byxTS5  Instagram: https://bit.ly/3Rii1cS  TikTok: https://bit.ly/4hiQaEe  Facebook: https://bit.ly/4iUS5zL  LinkedIn: https://bit.ly/4kW5hGq  Thank you to our partners: H2TABS - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH - USE CODE “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD - USE CODE "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP - SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE - THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP - GET 1 FREE MONTH WHEN YOU JOIN!: https://bit.ly/3VQ0nzW MASA CHIPS - GET 20% OFF YOUR FIRST $50+ ORDER: https://bit.ly/40LVY4y VANDY - USE CODE “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE PARKER PASTURES - PREMIUM GRASS-FED MEATS: https://bit.ly/4hHcbhc AION - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD HAPBEE - FEEL BETTER & PERFORM AT YOUR BEST: https://bit.ly/4a6glfo CARAWAY - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF - GET 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/4inFfd7 RHO NUTRITION - USE CODE “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka: Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X.com: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps: 00:00 Intro 02:49 Taylor Dukes' Health Journey 1.0 10:28 Journey 2.0: Diagnosis and Healing from a Brain Tumor 19:28 Impact of Mindset and Healthy Diet 23:35 Undergoing through Different Treatments (Vitamin C, Methylene Blue Infusions, Red Light Therapy, Molecular Hydrogen Oxygen, and Metabolic Ketosis) 26:13 Elimination of Mold, Mycotoxin, Metals, and Virus 27:19 Link of Parasites and Cancer 30:52 Shrinkage of the Tumor in Half 34:55 Treating Lyme Disease 37:01 Stress-Reducing Techniques 41:05 Caring for Our Gut Health 44:48 Practical Steps Every Mom Should Know About 52:58 Taylor's Online Community 54:50 Final Question: What does it mean to you to be an “Ultimate Human?” The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices

El vocalista de La Arrolladora se confiesa con total honestidad en un podcast/entrevista cargada de fuertes emociones. El sufrimiento para llegar a la cima, la llegada a la banda de sus sueños, el hate recibido en sus inicios, la relación con Josi Cuen y Vincen, el grave problema de salud que tuvo que enfrentar y varias situaciones de extremo peligro en las carreteras mexicanas, ESAÚL GARCÍA, una vida llena de grandes DESAFÍOS.

Health advocate and tumor survivor Lindsay Mayer joins me on the podcast this week to talk about her journey of being diagnosed with a rare facial tumor, an Ameloblastoma, in her chin bone. Having recently gotten married and having had her first child this was the last thing she thought would happen. She walks me through her journey with it, advocating for her health and helping others all around the world with their health journies. This is a story of grit, grace, and gratitude for life and how precious it is. Find Us:https://loveyouevenmore.com/TikTok: @shapedbylindsayIG: @lindsaydmayerSupport the show

Send us a textBumps and lumps of the hand can be any number of things...  all are classified as a hand tumor, but do they all require treatment, and which are a cause for concern? Host Debra Schindler explores the various types of hand tumors from the benign to malignant, with hand surgeon and Chief of the Curtis National Hand Center, Dr. James Higgins, and orthopedic oncologist, Dr. Mohammed Karim. Learn about the variety of hand tumors, treatment options, and the importance of early diagnosis. Don't let uncertainty hold you back— peace of mind is everything.   If you have concerns about a hand tumor and would like to see a specialist call 877-34-ORTHO  or 877-346-7846.  If you're from outside the Maryland area, ask for a video consult appointment. If you would like to provide feedback on this podcast, or get more information on hand tumors, send Debra an email:  debra.schindler@medstar.net.   For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

I’m going to beat this cancer or die trying. Actor Michael Landon   Clips Played:  Peggy that’s the recipe for mustard gas (original in pinned and desc.) (youtube.com)     This study DOUBLED cancer survivorship, challenging 100 years of treatment methodology. (youtube.com)    Chemical Weapons of WW1 – Horrific Weapons of War – No1 – […] The post NEW: Dr. Seyfried -Radiation and Steroids ALSO Drive Sugar HIGHER- Tumor Growth. Mustard Gas & Chemo.  Procedures to Make It WORSE, Not Better.  No Improvement or Change in Cancer Treatment 100 Years.  Wonder Why?  Dr. Cornelius Rhoads and Puerto Rico. appeared first on Psychopath In Your Life.

Send us a textIn this unique episode, Laura Kenny Penn State extension educator and owner of Frankie, our Standardbred broke to ride at age 21, and Dr. Kelsey Jurek, board certified surgeon and assistant professor at Oregon State University College of Veterinary Medicine educate us on keratomas!  These benign tumors are found within the hoof, but are a real pain for the horse and owner alike!  Learn how they are treated, and how to keep a 25 year old horse happy with stall rest!

Dr. Betsy Young, a physician-scientist from UCSF provides an overview of her funded work: Tumor cGAS-STING repression drives immune evasion in osteosarcoma and is therapeutically targetable via host STING activation. This work was funded by an MIB Agents 2024 OutSmarting Osteosarcoma YI Hope grant Because of Charlotte.Osteosarcoma (OS) has an immunosuppressive macrophage-rich, T-cell-depleted tumor microenvironment (TME). By performing bulk RNA seq of OS cell lines treated with STING agonist, the lab has defined an OS-specific STING activation signature, which demonstrated a significant protective effect on survival in OS patient samples. In immunocompetent OS models, systemic STING agonism shows curative anti-tumor effects, shifts the tumor microenvironment towards a pro-inflammatory phenotype, and induces immunologic memory. Importantly, host STING activation is sufficient to promote this anti-tumor immunity. The lab has demonstrated that STING activation has anti-tumor benefit in animal models and a protective effect in the human disease, nominating this innate immune sensing pathway as an important therapeutic target in OS.As a physician-scientist and a pediatric oncologist, Dr. Young's aim is to advance the field of pediatric oncology in her research career focused on the immunobiology of osteosarcoma. She completed her Pediatric Hematology/Oncology fellowship training at UCSF, receiving strong clinical training in high-risk pediatric solid tumors and early-phase clinical trials. Now, as a faculty member, she is investigating the pathogenesis of osteosarcoma metastasis in the Sweet-Cordero lab at UCSF, with a specific focus on immuno-oncology translational therapeutics.

A medical test used to detect cancer may actually be causing cancerous tumors, research suggests. Computerized tomography (CT) scans use X-rays to create detailed images of the body and are used to diagnose and monitor diseases like cancer and bone injuries, as well as to assist in surgeries and evaluate efficacy of certain treatments.  Special Guest – Dr. James LaValle – ‘What YOU Need to Know for a Healthy Heart' 

Çdo mëngjes zgjohuni me “Wake Up”, programi i njëkohshëm radio-televiziv i “Top Channel” e “Top Albania Radio”, në thelb ka përcjelljen e informacionit më të nevojshëm për mëngjesin. Në “Wake Up” gjeni leximin e gazetave, analiza të ndryshme, informacione utilitare, këmbimin valuator, parashikimin e motit, biseda me të ftuarit në studio për tema të aktualitetit, nga jeta e përditshme urbane e deri tek arti dhe spektakli si dhe personazhe interesantë. Zgjimi në “Wake Up” është ritmik dhe me buzëqeshje. Gjatë tri orëve të transmetimit, na shoqëron edhe muzika më e mirë, e huaj dhe shqiptare. 

En este programa, Frank ofrece orientación para reducir nódulos y tumores.

Send us a textShort Summary: How dietary fructose affects the growth rate of cancer.About the guest: Gary Patti, PhD is a professor at Washington University in St. Louis, holding appointments in chemistry, medicine, and geneticsNote: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Full transcript and other information on Substack.Episode Summary: Nick Jikomes talks to Dr. Patti, exploring how cancer cells metabolize sugars like glucose and fructose, focusing on a recent study showing fructose indirectly boosts tumor growth in mice via liver-produced lipids called LPCs. The discussion covers cancer biology basics, Warburg effect, tumor microenvironments, and systemic metabolic impacts of cancer, while also touching on dietary implications, fasting, and the complexities of nutrient use in cancer progression.Key Takeaways:Cancer cells often rely heavily on glucose, excreting it as lactate even when oxygen is available (Warburg effect), but take up more than their mitochondria can handle.In a study, high fructose diets accelerated tumor growth in mice by 4x, not because cancer cells use fructose directly, but because the liver converts it to LPCs, which tumors use to build membranes.Tumors are not just cancer cells; they recruit healthy cells in their microenvironment, and their metabolic effects ripple across the entire body, altering distant tissues.Excessive fructose consumption may worsen tumor growth, but cutting it poses little risk and could benefit cancer patients, pending human studies.Fasting may reduce cancer initiation risk in animals, but its effect on existing tumors is less clear and could worsen wasting (cachexia) in late stages.The body tightly regulates blood glucose via the liver, so simply cutting dietary glucose won't starve tumors, highlighting cancer's metabolic adaptability.Related episode:M&M #200: Dietary Fats & Seed Oils in Inflammation, Colon CancerSupport the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts

Are you dealing with mysterious or persistent symptoms? Have they led you to unsettling health news? If so, I invite you to tune into this episode where we'll quickly plug you back into *knowing* the BODY's wisdom and the truth about root-cause healing. This story will blow your mind from start to finish. Join me and Amanda Wilkes, a 5th-year Fiercely Empowered Mama and the newest member of my team, as we dive into: Her hubby's mysterious and lingering GI issues. The escalation that led them to go to an urgent care the day before the Super Blue Moon. Living through the unknown of ongoing medical testing. Experiencing the shock, fear and alarm that comes with unexpected news. What it looks like to hold space for someone you love — even when they make decisions that you wouldn't necessarily make for yourself. How in hindsight allows us to see the perfection in Divine timing. The REAL cause of her husband's symptoms, his natural health journey to FULL healing and the MANY miracle moments along the way. We also talk about the driving force behind Amanda's YES to join Fiercely Empowered Mama at the end of 2020, and few of the HUGE health wins and upgrades that she's experienced in FEM and the Cleansing Circle.  And yes, we chat about why we're both obsessed with enemas! About Amanda Amanda Wilkes is a 5th-year Fiercely Empowered Mama and the newest member of TeamTonya. You'll find her helping you navigate cleansing in the Cleansing Circle and leading Muscle Testing classes in Fiercely Empowered Mama.    Hooking You Up! Body Talk What if you knew exactly what your body was trying to tell you? Isn't it time you understand the meaning behind the messages that have been in front of you this whole time? Join me in Body Talk, where you'll learn the love language of YOUR body. Follow this link to learn more.   The Cleansing Circle YOU get to decide what's possible when it comes to your health story. Our bodies are slowly being poisoned by the toxic load in our environment. But in the Cleansing Circle, you'll learn just how simple it can be to embrace TRUE cleansing as part of your life. No matter what your story is, we have highly effective and SAFE cleansing options designed for everyone. Join a circle of women for a group coaching experience that will have an immediate impact on your health. Follow this link to learn more.   Fiercely Empowered Mama Raise your child naturally, feeling confident, empowered and free. What if you trusted your mama intuition and instincts — fully, above anyone else — and you knew how to tune into your child at any given moment to see what support they needed most? Fiercely Empowered Mama is proven to help you shift from fear to FREEDOM by giving you the knowledge, confidence and empowerment to become the HEALER of your home. Follow this link to learn more and get on the waitlist for FEM 2026. When you're on the waitlist, you'll be the FIRST to know when the doors open and you'll get access to the very BEST pricing.   FEMfusion Mineralization & Ultimate Hydration Right now, one out of every three people in the U.S. is deficient in at least 10 minerals. And minerals are the sparks of life! FEMfusion is my tried-and-true go-to herbal infusion blend that's made with herbs that shine as incredible sources of minerals, vitamins and more — and it's loaded with antioxidants! Because it's so hydrating, you'll feel an instant boost when you drink it! Follow this link to get started on deeper mineralization and hydration today.  

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Do you ever wish you could be a fly on the wall at a tumor board meeting? In this episode of BackTable, we're excited to give you an insider's view of the real case discussions that take place during hepatocellular carcinoma (HCC) tumor boards. Host Dr. Zach Berman sits down with a multidisciplinary team, including Drs. Adam Burgoyne (medical oncologist), Heather Patton (hepatologist), Siddharth Padia (interventional radiologist), and Gabriel Schnickel (transplant and hepatobiliary surgeon). Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125743 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The team walks through a range of diverse HCC cases, reviewing patient histories, imaging, and treatment options. They cover eight cases in total, each featuring patients with varying treatment histories, comorbidities, liver function, and lesion characteristics. For the full educational experience, we recommend watching the video format on our YouTube channel. --- TIMESTAMPS 00:00 - Introduction 00:47 - Case 1: Small Lesion in a Young Patient 05:01 - Case 2: Moderate Sized Lesion in an Older Patient 11:10 - Case 3: Multifocal HCC with Dominant Lesion 21:09 - Case 4: Dominant Lesion with Portal Hypertension 32:08 - Case 5: Ruptured Solitary Lesion 34:34 - Case 6: Rupture with Multifocal Lesions 44:08 - Case 7: Portal Vein Invasion 52:12 - Case 8: Metastatic HCC After Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Sunshine and Kalani are in the lounge to catch up on the last few weeks of worldwide drama and shenanigans. We review the Hula Hula room in Torrance, sip on a ZTL Mai Tai, share our upcoming Tiki Caliente room party plans and worry about the end of the world. Perfect conversation for a dimly lit tiki bar with friends.

Osteomas... Osterosarcomas... Chondrosarcomas... they all sound so similar! MS3 Angia Chen will clarify these differences by discussing the high yield concept of bone tumors.

Neue Hoffnung auf verträglichere Krebsbehandlung – Moderne Medizin kann viele Krebsarten behandeln. Doch oft belastet die Behandlung den Körper zusätzlich. Forschende in Freiburg haben möglicherweise einen Weg gefunden, sie mit UV-Licht verträglicher zu machen.

On Today’s Show: 00:00:00  Introduction 04:48:18  Customer Phone Call Meltdown 07:22:16  Angry Voicemail After One Date 11:45:22  Daddy’s Emotional Abuse 14:13:05  Carrying Your Breast Tumor To Full Term 19:16:05  A Wanking Nikocado Avocado Crashes A Zoom Meeting  20:43:24  Thursday Lane Returns 25:12:04  Sign Up For The Sideshow! 26:44:06  Vladimir Putin In Dick Form 30:00:20  Setting […] The post Carrying Your Breast Cancer Tumor To Full Term first appeared on Distorted View Daily.

Celebrities flee California wildfires (23:19)Zach Bryan Claps Back at Trolls in Explosive Instagram Rant After Brianna LaPaglia Split (PEOPLE) (28:24)Karen Huger checks into rehab after DUI convictions, skips 'RHOP' Season 9 reunion taping (Page Six) (38:37)Oprah Winfrey, Simone Biles, Kermit the Frog and More Stars Surprise Hoda Kotb on Final Today Broadcast (PEOPLE) (48:42)Madison LeCroy Reveals Husband Brett Found a Tumor on His Kidney After Thyroid Cancer (PEOPLE) + Southern Charm Recap (52:26)Queenie and Weenie of The Week (57:04)The Toast with Jackie (@JackieOshry) and Claudia Oshry (@girlwithnojob) Lean InThe Camper and The Counselor by Jackie OshryMerchThe Toast PatreonGirl With No Job by Claudia OshrySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.